ShockWave Medical, Inc.
SWAV · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 2.31 | 1.51 | 2.58 | -3.46 |
| FCF Yield | 0.23% | 0.90% | 0.60% | 0.30% |
| EV / EBITDA | 222.04 | 156.95 | 150.07 | 307.02 |
| Quality | ||||
| ROIC | 3.02% | 2.43% | 2.42% | 4.00% |
| Gross Margin | 87.11% | 87.53% | 86.82% | 86.41% |
| Cash Conversion Ratio | 0.65 | 1.62 | 1.45 | 1.38 |
| Growth | ||||
| Revenue 3-Year CAGR | 38.15% | 45.48% | 56.34% | 67.97% |
| Free Cash Flow Growth | -56.83% | 44.13% | 42.35% | 15.74% |
| Safety | ||||
| Net Debt / EBITDA | 8.83 | 9.28 | 5.27 | -2.44 |
| Interest Coverage | 14.41 | 15.11 | 17.39 | 39.97 |
| Efficiency | ||||
| Inventory Turnover | 0.25 | 0.24 | 0.25 | 0.27 |
| Cash Conversion Cycle | 374.63 | 401.74 | 379.39 | 339.35 |